Skip to main content
Top
Published in: Psychiatric Quarterly 2/2007

01-06-2007 | Original Paper

Changes in the Treatment of Acute Psychosis in a German Public Hospital from 1998 to 2004

Authors: Tiemo Wessels, M.D., Dandy Grünler, M.D., Christa Bunk, Michael Specka, Ph.D., Markus Gastpar, M.D., Norbert Scherbaum, M.D., Eugen Davids, M.D.

Published in: Psychiatric Quarterly | Issue 2/2007

Login to get access

Abstract

Introduction

The aim of our study was to investigate antipsychotic treatment strategies in acute schizophrenic episodes in a German university hospital.

Methods

Documented pharmacological procedures in the first six weeks of acute episodes of schizophrenia in the years 1998 (n = 108), 2001 (n = 92), and 2004 (n = 94) were analyzed. Inclusion criteria were: admission voluntary and involuntary as inpatient to our acute ward with a diagnosis of F20× according to ICD 10.

Results

Atypical antipsychotics (AAP) were significant more frequently used in the first week of treatment in 2001 and 2004 compared to the year 1998. Switching to AAP occurred significantly earlier in 2001 and 2004 (after 7,6 ± 7 days in 1998, 3,5 ± 5 days in 2001 and 2,3 ± 5 days in 2004; < 0.002). In all three years prescription of high potent typical antipsychotics decreased during the first six weeks of treatment. Involuntary treatment (< 0.001) and age (P = 0.001) were significantly correlated to initial prescription of AAP. Involuntary admitted patients received more often a combination of high-potent conventional high potent typical neuroleptics and AAP (48% vs. 24%, P = 0.007).

Conclusion

Second generation atypicals are used more frequently according to current guidelines and switching from conventional medications occurs earlier.
Literature
1.
go back to reference Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone, haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 346:16–22, 2002.PubMedCrossRef Csernansky JG, Mahmoud R, Brenner R: A comparison of risperidone, haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 346:16–22, 2002.PubMedCrossRef
2.
go back to reference Emsley RA, Raniwalla J, Bailey PJ, et al: A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. International Clinical Psychopharmacology 15:121–131, 2000.PubMed Emsley RA, Raniwalla J, Bailey PJ, et al: A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. International Clinical Psychopharmacology 15:121–131, 2000.PubMed
3.
go back to reference Gomez JC, Crawford AM: Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Journal of Clinical Psychiatry 62 (Suppl 2):6–11, 2001.PubMed Gomez JC, Crawford AM: Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial. Journal of Clinical Psychiatry 62 (Suppl 2):6–11, 2001.PubMed
4.
go back to reference Kasper S, Lerman MN, McQuade RD, et al: Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 6:325–337, 2003.PubMedCrossRef Kasper S, Lerman MN, McQuade RD, et al: Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. International Journal of Neuropsychopharmacology 6:325–337, 2003.PubMedCrossRef
5.
go back to reference American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. 2006. Available at: www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. 2006. Available at: www.psych.org/psych_pract/treatg/pg/SchizPG-Complete-Feb04.pdf.
6.
go back to reference Gaebel W, Weinmann S, Sartorius N, et al: Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry 187:248–255, 2005.PubMedCrossRef Gaebel W, Weinmann S, Sartorius N, et al: Schizophrenia practice guidelines: international survey and comparison. British Journal of Psychiatry 187:248–255, 2005.PubMedCrossRef
7.
go back to reference De Hert M, van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. International Clinical Psychopharmacology 21 (Suppl 2):S11–S15, 2006.PubMedCrossRef De Hert M, van Eyck D, De Nayer A: Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. International Clinical Psychopharmacology 21 (Suppl 2):S11–S15, 2006.PubMedCrossRef
8.
go back to reference Grohmann R, Engel RR, Geissler KH, et al: Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 (Suppl 1):S27–S38, 2004.PubMed Grohmann R, Engel RR, Geissler KH, et al: Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 (Suppl 1):S27–S38, 2004.PubMed
9.
go back to reference Centorrino F, Goren JL, Hennen J, et al: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. American Journal of Psychiatry 161:700–706, 2004.PubMedCrossRef Centorrino F, Goren JL, Hennen J, et al: Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. American Journal of Psychiatry 161:700–706, 2004.PubMedCrossRef
10.
go back to reference Gaebel W, Riesbeck M, Janssen B, et al: Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions. European archives of psychiatry and clinical neuroscience 253:175–184, 2003.PubMedCrossRef Gaebel W, Riesbeck M, Janssen B, et al: Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders. Drug choice, switching and outcome under naturalistic treatment conditions. European archives of psychiatry and clinical neuroscience 253:175–184, 2003.PubMedCrossRef
11.
go back to reference Davids E, Bunk C, Specka M, et al: Psychotropic drug prescription in a psychiatric university hospital in Germany. Progress in neuro-psychopharmacology and bi ological psychiatry, 30 (6):1109–16, 2006.CrossRef Davids E, Bunk C, Specka M, et al: Psychotropic drug prescription in a psychiatric university hospital in Germany. Progress in neuro-psychopharmacology and bi ological psychiatry, 30 (6):1109–16, 2006.CrossRef
12.
go back to reference Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Journal of Clinical Psychiatry 65:1377–1388, 2004.PubMedCrossRef Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. Journal of Clinical Psychiatry 65:1377–1388, 2004.PubMedCrossRef
13.
go back to reference Centorrino F, Fogarty KV, Sani G, et al: Antipsychotic drug use: McLean Hospital, 2002. Human Psychopharmacology 20:355–358, 2005.PubMedCrossRef Centorrino F, Fogarty KV, Sani G, et al: Antipsychotic drug use: McLean Hospital, 2002. Human Psychopharmacology 20:355–358, 2005.PubMedCrossRef
14.
go back to reference Weinmann S, Janssen B, Gaebel W: Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Journal of Clinical Psychiatry 65:1099–1105, 2004.PubMed Weinmann S, Janssen B, Gaebel W: Switching antipsychotics in inpatient schizophrenia care: predictors and outcomes. Journal of Clinical Psychiatry 65:1099–1105, 2004.PubMed
15.
go back to reference Covell NH, Jackson CT, Evans AC, et al: Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28:17–29, 2002.PubMed Covell NH, Jackson CT, Evans AC, et al: Antipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing styles. Schizophrenia Bulletin 28:17–29, 2002.PubMed
16.
go back to reference Rittmannsberger H, Meise U, Schauflinger K, et al: Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur opean Psychiatry 14:33–40, 1999.CrossRef Rittmannsberger H, Meise U, Schauflinger K, et al: Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur opean Psychiatry 14:33–40, 1999.CrossRef
17.
go back to reference Ananth J, Parameswaran S, Gunatilake S: Antipsychotic polypharmacy. Current Pharmaceutical design 10:2231–2238, 2004.PubMedCrossRef Ananth J, Parameswaran S, Gunatilake S: Antipsychotic polypharmacy. Current Pharmaceutical design 10:2231–2238, 2004.PubMedCrossRef
18.
go back to reference Schussler G, Muller-Oerlinghausen B: Polypharmacy in psychiatric practice. Comprehensive Psychiatry 25:566–574, 1984.PubMedCrossRef Schussler G, Muller-Oerlinghausen B: Polypharmacy in psychiatric practice. Comprehensive Psychiatry 25:566–574, 1984.PubMedCrossRef
19.
go back to reference Antai-Otong D: The art of prescribing. Principles of switching novel antipsychotic medications. Perspectives in Psychiatric Care 41:45–47, 2005.PubMedCrossRef Antai-Otong D: The art of prescribing. Principles of switching novel antipsychotic medications. Perspectives in Psychiatric Care 41:45–47, 2005.PubMedCrossRef
20.
go back to reference Casey DE, Carson WH, Saha AR, et al: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391–399, 2003. Casey DE, Carson WH, Saha AR, et al: Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391–399, 2003.
21.
go back to reference Weiden PJ, Simpson GM, Potkin SG, et al: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Journal of Clinical Psychiatry 64:580–588, 2003.PubMedCrossRef Weiden PJ, Simpson GM, Potkin SG, et al: Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. Journal of Clinical Psychiatry 64:580–588, 2003.PubMedCrossRef
22.
go back to reference Simpson GM, Glick ID, Weiden PJ, et al: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161:1837–1847, 2004.PubMedCrossRef Simpson GM, Glick ID, Weiden PJ, et al: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161:1837–1847, 2004.PubMedCrossRef
23.
go back to reference Leslie DL, Rosenheck RA: From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. American Journal of Psychiatry 159:1534–1540, 2002.PubMedCrossRef Leslie DL, Rosenheck RA: From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. American Journal of Psychiatry 159:1534–1540, 2002.PubMedCrossRef
24.
go back to reference Rothbard AB, Kuno E, Foley K: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29:531–540, 2003.PubMed Rothbard AB, Kuno E, Foley K: Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophrenia Bulletin 29:531–540, 2003.PubMed
25.
go back to reference Hugenholtz GW, Heerdink ER, Meijer WE, et al: Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 38:122–124, 2005.PubMedCrossRef Hugenholtz GW, Heerdink ER, Meijer WE, et al: Reasons for switching between antipsychotics in daily clinical practice. Pharmacopsychiatry 38:122–124, 2005.PubMedCrossRef
26.
go back to reference Ereshefsky L: Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Journal of Clinical Psychiatry 60 (Suppl 10):20–30, 1999.PubMed Ereshefsky L: Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. Journal of Clinical Psychiatry 60 (Suppl 10):20–30, 1999.PubMed
27.
go back to reference Tulloch KJ, Zed PJ: Intramuscular olanzapine in the management of acute agitation. The Annals of Pharmacotherapy 38:2128–2135, 2004.PubMedCrossRef Tulloch KJ, Zed PJ: Intramuscular olanzapine in the management of acute agitation. The Annals of Pharmacotherapy 38:2128–2135, 2004.PubMedCrossRef
28.
29.
go back to reference Johns CA, Thompson JW: Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin 21:607–619, 1995.PubMed Johns CA, Thompson JW: Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy. Schizophrenia Bulletin 21:607–619, 1995.PubMed
30.
go back to reference Voirol P, Robert PA, Meister P, et al: Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 32:29–37, 1999.PubMedCrossRef Voirol P, Robert PA, Meister P, et al: Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 32:29–37, 1999.PubMedCrossRef
Metadata
Title
Changes in the Treatment of Acute Psychosis in a German Public Hospital from 1998 to 2004
Authors
Tiemo Wessels, M.D.
Dandy Grünler, M.D.
Christa Bunk
Michael Specka, Ph.D.
Markus Gastpar, M.D.
Norbert Scherbaum, M.D.
Eugen Davids, M.D.
Publication date
01-06-2007
Published in
Psychiatric Quarterly / Issue 2/2007
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-006-9030-y

Other articles of this Issue 2/2007

Psychiatric Quarterly 2/2007 Go to the issue